Abbott receives U.S. approval of next-generation MitraClip, bringing new enhancements to Abbott's leading MitraClip platform
advertisement
当前地点:
>
>
> This Story

Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Cardiology Homepage

Adagio Medical announces US FDA investigational device exemption approval for atrial fibrillation trial with cryoablation

Philips unveils HeartStart Intrepid with IntelliSpace Connect across Europe and select markets worldwide

FDA expands indication for several transcatheter heart valves

Edwards SAPIEN 3 TAVR receives FDA approval for low-risk patients

The power of 4D technology advances care for heart patients

AtriCure enters into definitive agreement to acquire SentreHEART

Ancora Heart enrolls first patient in European multi-center study of first-of-its-kind investigational heart failure therapy

First TAVR procedure performed at Henry Ford Macomb Hospital

Endologix receives IDE approval for the Nellix Chimney EndoVascular Aneurysm Sealing Protocol

Transport by mobile stroke units get patients quicker treatment than ambulance

Abbott receives U.S. approval of next-generation MitraClip, bringing new enhancements to Abbott's leading MitraClip platform

Press releases may be edited for formatting or style
ABBOTT PARK, Ill., July 15, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the company has received U.S. Food and Drug Administration (FDA) approval for the most advanced MitraClip™ heart valve repair device to treat mitral regurgitation. The latest approval for the fourth-generation MitraClip device, MitraClip G4, puts new enhancements into the hands of physicians across the U.S. by delivering an expanded range of clip sizes, an alternative leaflet grasping feature and facilitation of procedure assessment in real time to offer doctors further options when treating mitral valve disease.

The MitraClip device repairs leaky mitral valves without open-heart surgery and is delivered to the heart through a small incision in the leg. The device clips portions of the leaflets, or flaps, of the mitral valve together to reduce the backflow of blood (known as mitral regurgitation, or MR), restoring the heart's ability to pump oxygenated blood more efficiently. To date, MitraClip has helped treat more than 80,000 people worldwide suffering from both primary and secondary MR and is supported by the industry's most extensive body of clinical evidence, including the recent results of the landmark COAPT™ Trial published in The New England Journal of Medicine in September 2018.

Story Continues Below Advertisement

Servicing GE/Siemens Nuclear Medicine equipment with OEM trained engineers

Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.



As part of an ongoing, patient-centric product development cadence, Abbott has expanded MitraClip to a total of four clip sizes – now including clips with wider grasping area – to provide physicians additional options for treatment. MitraClip G4 also offers independently controlled grippers that allow physicians to grasp one or both leaflets during the procedure, known as Controlled Gripper Actuation™.

"We are continually innovating the MitraClip technology based on the experience of the physicians implanting the device so we can truly help them improve the lives of their patients," said Neil Moat, M.D., chief medical officer of Abbott's structural heart business. "With the fourth generation of MitraClip, we set out to build a system that would help physicians individualize the therapy to each patient and deliver even more features that can treat both primary and secondary mitral regurgitation."

In addition to four clip sizes and the leaflet grasping feature, the latest generation of MitraClip offers the benefit of an upgraded catheter to allow integrated real-time continuous left atrial pressure monitoring during implant. The feature allows physicians to use a commercially available pressure monitor integrated into the MitraClip catheter to continuously monitor and confirm MR reduction during the implant procedure and help them determine whether MitraClip should be repositioned or placed differently to optimize patient outcomes.
  Pages: 1 - 2 >>

Cardiology Homepage


You Must Be Logged In To Post A Comment